<DOC>
	<DOCNO>NCT03042689</DOCNO>
	<brief_summary>This research study study drug possible treatment advance myeloid malignancy include AML ( acute myeloid leukemia ) , MDS ( myelodysplastic syndrome ) MPN ( myeloproliferative neoplasm ) The intervention involve study : -Regorafenib ( Stivarga )</brief_summary>
	<brief_title>Study Regorafenib Patients With Advanced Myeloid Malignancies</brief_title>
	<detailed_description>This research study Phase I clinical trial , test safety investigational drug also try define appropriate dose investigational drug use study . `` Investigational '' mean drug study . The FDA ( U.S. Food Drug Administration ) approve Regorafenib specific disease approve us . In research study , investigator look best dose Regorafenib treat participant 's disease . Researchers also look effective study drug treat participant 's disease side effect occur .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Diagnosis relapsed/refractory advance malignancy . Specifically : relapsed refractory refractory acute myeloid leukemia fail one line prior therapy , myelodysplastic syndrome fail hypomethylating agent , myelofibrosis fail ruxolitinib ineligible therapy . 18 year age great . ECOG performance status 01 . Able provide inform consent . Subjects ( men woman ) childbearing potential must agree use adequate contraception begin sign ICF least 2 month last dose study drug . The definition adequate contraception base judgment principal investigator designate associate . Able swallow retain oral medication . Normal organ marrow function define : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) except patient Gilbert 's disease . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 x ULN ( ≤ 5 x ULN subject liver involvement cancer ) . Alkaline phosphatase limit ≤ 2.5 x ULN ( ≤ 5 x ULN subject liver bone involvement cancer ) . Serum creatinine ≤ 1.5 x ULN . International normalized ratio ( INR ) / Partial thromboplastin time ( PTT ) ≤ 1.5 x ULN . ( Subjects prophylactically treat agent warfarin heparin allow participate provide prior evidence underlie abnormality coagulation parameter exist . ) Previous assignment treatment study . Subjects permanently withdraw study participation allow reenter study . Systemic antineoplastic therapy past 14 day ( exclude hydroxyurea ) . Uncontrolled hypertension ( systolic pressure &gt; 140 mmHg diastolic pressure &gt; 90 mmHg repeat measurement ) despite optimal medical management . Active clinically significant cardiac disease include : Congestive heart failure New York Heart Association ( NYHA ) &gt; Class II . Active coronary artery disease . Cardiac arrhythmia require antiarrhythmic therapy beta blocker digoxin . Unstable angina ( anginal symptom rest ) , newonset angina within 3 month randomization , myocardial infarction within 6 month randomization . Evidence history bleed diathesis coagulopathy . Eligible , suitable donor willing undergo Hematopoietic Stem Cell Transplantation ( HSCT ) Any hemorrhage bleeding event ≥ NCI CTCAE Grade 3 within 4 week prior start study medication . Thrombotic , embolic , venous arterial event , cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism within 6 month inform consent . Previously untreated concurrent cancer distinct primary site histology except cervical cancer insitu , treat ductal carcinoma situ breast , curatively treat nonmelanoma skin carcinoma , noninvasive aerodigestive neoplasm superficial bladder tumor . Subjects survive cancer curatively treat without evidence disease 3 year registration allow . All cancer treatment must complete least 3 year prior registration . Known history human immunodeficiency virus ( HIV ) infection current chronic active hepatitis B C infection require treatment antiviral therapy . Presence nonhealing wound , nonhealing ulcer bone fracture . Major surgical procedure significant traumatic injury within 28 day start study medication . Renal failure require hemoor peritoneal dialysis . Seizure disorder require medication . Persistent proteinuria ≥ Grade 3 NCICTCAE v4.0 ( &gt; 3.5 g/24 hr , measure urine protein : creatinine ratio random urine sample ) . Interstitial lung disease ongoing sign symptoms time informed consent . Pleural effusion ascites cause respiratory compromise ( ≥ NCICTCAE version 4.0 Grade 2 dyspnea ) . History organ allograft ( include corneal transplant ) . Known suspected allergy hypersensitivity study drug , study drug class , excipients formulation give course trial . Any malabsorption condition . Women pregnant breastfeeding , intend become pregnant study . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start study drug . Postmenopausal woman ( defined menses least 1 year ) surgically sterilize woman require undergo pregnancy test . Substance abuse , medical , psychological social condition may interfere subject 's participation study evaluation study result . Presence unresolved toxicity prior anticancer therapy , define resolve NCI CTCAE v4.03 grade 0 1 exception alopecia . Subjects irreversible toxicity reasonably expect exacerbated regorafenib ( e.g . hearing loss , neuropathy ) may include consultation principal investigator . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , uncontrolled hypertension , unstable angina pectoris , uncontrolled cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>AML</keyword>
</DOC>